Study wrapper · #1261
Exploring The Role of GLP-1 Receptor Agonists and DPP4 Inhibitors in the Treatment of Opioid Use Disorder: A Scoping Review.
Editor's note
The signal is consistent in direction but almost entirely preclinical and retrospective, which is exactly the pattern that dissolves under randomisation. Observational cohorts of people prescribed semaglutide differ systematically from those who are not, and the authors say as much in calling for controlled trials. Worth logging as an early lead: three ongoing randomised trials will decide this, and the single existing RCT is not yet peer-reviewed. No claim about clinical benefit is supportable today.
Plain-language abstract
A scoping review of 21 studies asking whether GLP-1 drugs and DPP4 inhibitors have any role in opioid use disorder. Most of the 13 rodent studies found less opioid-seeking behaviour, and four observational human studies linked GLP-1 drugs — semaglutide in particular — with lower rates of opioid overdose and substance use. Only one randomised trial has appeared, as a preprint, with three more underway.